Delay up the progression of chronic kidney disease (CKD) is still an unsolved problem. The suppression of known ‘causes’ of progression by targeting high blood pressure as well as the renin–angiotensin system (RAS) has met with some success in REIN, RENAAL, IDNT, and other clinical trials [ 1–3]. However, although these therapies slow the progression of CKD, the residual risk of these patients for both renal and cardiovascular end points remains high. Since the pathogenesis of renal progressive disease is multifactorial, a combined therapy strategy may be the way for the future to completely block renal disease progression. An interesting result of such a combined therapy strategy came from the COOPERATE trial [combining ACE-inhibition with angiotensin-II-receptor-blockade (ACEi/ARB)], targeting the same hormonal systems from different angles [ 4]. Other strategies target different pathophysiologically important systems at the same time, such as RAS and glycosaminoglycans [ 5], and RAS and endothelin [ 6]. Recent evidence supports the theory that active vitamin D and its analogues attenuate glomerular and tubular interstitial fibrosis. Could vitamin D become an additional therapeutic agent for CKD? The present review will focus primarily on the most recent advances in our understanding of the potential therapeutic roles of calcitriol and its analogues in the area of CKD.